Report Sections

See All Reports

  • HP:0002180: Neurodegeneration
  • Pneumonia (359) Respiratory tract infection (38) Neoplasm (36) Abnormality of the cardiovascular system (34) Diabetes mellitus (33) Depressivity (29) Acute kidney injury (27) Hypoxemia (26) Hypertension (24) Abnormal lung morphology (24) Thromboembolism (22) Anosmia (20) Myocardial infarction (20) Arthritis (19) Type II diabetes mellitus (18) Stroke (16) Pulmonary embolism (16) Mental deterioration (15) Abnormality of coagulation (15) Pulmonary fibrosis (15) Chronic pulmonary obstruction (15) Abnormality of the kidney (14) Autistic behavior (14) Rheumatoid arthritis (14) Leukemia (14) Interstitial pneumonitis (14) Pulmonary obstruction (14) Asthma (13) Chronic pain (13) Congestive heart failure (12) Deep venous thrombosis (12) Neoplasm of the lung (12) Autism (11) Obesity (11) Respiratory distress (11) Colitis (11) Ulcerative colitis (11) Crohn's disease (11) Type I diabetes mellitus (10) Abnormality of the liver (9) Coronary artery atherosclerosis (9) Inflammation of the large intestine (9) Pulmonary insufficiency (9) Chronic kidney disease (9) Myocarditis (9) Behavioral abnormality (8) Psychosis (8) Dementia (8) Alzheimer disease (8) Carcinoma (8) Low levels of vitamin D (8) Sepsis (8) Infertility (7) Peripheral arterial stenosis (7) Renal insufficiency (6) Lymphopenia (6) Dysphagia (6) Lymphoma (6) Systemic lupus erythematosus (6) Osteoarthritis (6) Breast carcinoma (6) Psoriasiform dermatitis (6) Abnormality of the gastrointestinal tract (6) Fatigue (6) Encephalopathy (5) Premature birth (5) Bronchiectasis (5) Difficulty walking (5) Gastroparesis (5) Immunodeficiency (5) Obstructive sleep apnea (5) Autoimmunity (5) Knee osteoarthritis (5) Sleep apnea (5) Prostate cancer (5) Allergy (5) Non-small cell lung carcinoma (5) Schizophrenia (5) Neoplasm of the large intestine (5) Seizure (4) Hepatic fibrosis (4) Cardiac arrest (4) Weight loss (4) Migraine (4) Pulmonary arterial hypertension (4) Abnormal intestine morphology (4) Neoplasm of the pancreas (4) Colon cancer (4) Malnutrition (4) Paroxysmal atrial fibrillation (4) Disseminated intravascular coagulation (4) Attention deficit hyperactivity disorder (4) Inflammatory abnormality of the skin (4) Neoplasm of head and neck (4) Endometriosis (4) Addictive behavior (4) Hypercoagulability (4) Insomnia (4) Obsessive-compulsive behavior (3) Eczema (3) Atopic dermatitis (3) Spastic diplegia (3) Abnormal heart morphology (3) Cardiomyopathy (3) Fever (3) Hypothermia (3) Headache (3) Celiac disease (3) Reduced factor VIII activity (3) Lymphoid leukemia (3) Renal cell carcinoma (3) Abnormal anterior horn cell morphology (3) Amyotrophic lateral sclerosis (3) Cystoid macular edema (3) Arrhythmia (3) Cutaneous melanoma (3) Pulmonary edema (3) Ovarian neoplasm (3) Neuroendocrine neoplasm (3) Hypogeusia (2) Hearing impairment (2) Abnormality of the eye (2) Visual impairment (2) Conjunctivitis (2) Cataract (2) Uveitis (2) Agoraphobia (2) Abnormality of the endocrine system (2) Abnormality of the skin (2) Jaundice (2) Lymphedema (2) Spasticity (2) Meningitis (2) Abnormal joint morphology (2) Hepatic steatosis (2) Hepatic failure (2) Tachycardia (2) Angina pectoris (2) Pancreatitis (2) Abnormality of blood and blood-forming tissues (2) Thrombocytopenia (2) Autoimmune thrombocytopenia (2) Gout (2) Diarrhea (2) Gastroesophageal reflux (2) Apnea (2) Neurodegeneration (2) Alopecia of scalp (2) Mutism (2) Transient ischemic attack (2) Hyperkinetic movements (2) Polyphagia (2) Hypotension (2) Atherosclerosis (2) Hypoventilation (2) Squamous cell carcinoma (2) Myelodysplasia (2) Back pain (2) Low back pain (2) Muscular dystrophy (2) Stillbirth (2) Acute myeloid leukemia (2) Lymphoproliferative disorder (2) Myeloproliferative disorder (2) Multiple myeloma (2) Intervertebral disc degeneration (2) Stridor (2) Postprandial hyperglycemia (2) Hemeralopia (2) Arteritis (2) Hepatitis (2) Glioblastoma multiforme (2) Cervix cancer (2) Small cell lung carcinoma (2) Endocarditis (2) Toxemia of pregnancy (2) Myositis (2) Mania (2) Urinary retention (1) Urinary incontinence (1) Nephritis (1) Menorrhagia (1) Xerostomia (1) Otitis media (1) Conductive hearing impairment (1) Amblyopia (1) Periodontitis (1) IgA deposition in the glomerulus (1) Enuresis (1) Hypoparathyroidism (1) Adrenal insufficiency (1) Hyperaldosteronism (1) Osteopenia (1) Urticaria (1) Angiokeratoma corporis diffusum (1) Cholecystitis (1) Keratoconjunctivitis (1) Intellectual disability (1) Hemiparesis (1) Polyneuropathy (1) Syncope (1) Cerebral hemorrhage (1) Hepatocellular carcinoma (1) Intrauterine growth retardation (1) Hoarse voice (1) Dysphonia (1) Weak voice (1) Sudden cardiac death (1) Aortic valve stenosis (1) Bradycardia (1) Torsade de pointes (1) Atrioventricular block (1) Premature rupture of membranes (1) Dehydration (1) Constipation (1) Anorexia (1) Esophageal varix (1) Chorea (1) Status epilepticus (1) Subarachnoid hemorrhage (1) Abnormality of the spinal cord (1) Memory impairment (1) Encephalitis (1) Spina bifida (1) Language impairment (1) Waddling gait (1) Increased intracranial pressure (1) Biliary cirrhosis (1) Dilatation (1) Osteomyelitis (1) Central apnea (1) Hypokalemia (1) Hyponatremia (1) Hyperphosphatemia (1) Skeletal muscle atrophy (1) Male infertility (1) Spondylolisthesis (1) Myalgia (1) Bruxism (1) Neonatal death (1) Increased body weight (1) Intermittent claudication (1) Thrombophlebitis (1) Chronic bronchitis (1) Ventricular tachycardia (1) Acute myelomonocytic leukemia (1) Dilatation of the cerebral artery (1) Coronary artery stenosis (1) Venous insufficiency (1) Chronic lymphatic leukemia (1) Abnormality of bone marrow cell morphology (1) Hypersensitivity pneumonitis (1) Intraalveolar phospholipid accumulation (1) Neoplasm of the genitourinary tract (1) Neoplasm of the skin (1) Female infertility (1) Benign prostatic hyperplasia (1) Hip osteoarthritis (1) Bladder neoplasm (1) Stomatitis (1) Uterine neoplasm (1) Intestinal atresia (1) Placental abruption (1) Sinus tachycardia (1) Bronchiolitis (1) Erythroid hypoplasia (1) Asterixis (1) Hodgkin lymphoma (1) B-cell lymphoma (1) Ciliary dyskinesia (1) Myeloid leukemia (1) Chronic myelomonocytic leukemia (1) Morphea (1) Bronchitis (1) Hypercapnia (1) Pain (1) Retinal vein occlusion (1) Vasovagal syncope (1) Heart block (1) Cough (1) Neonatal asphyxia (1) Dyspareunia (1) Heart murmur (1) Cardiogenic shock (1) Cholangitis (1) Cholangiocarcinoma (1) Vulvar neoplasm (1) Neonatal sepsis (1) Glue ear (1) Abnormality of movement (1) Subdural hemorrhage (1) Biliary tract neoplasm (1) Nasal polyposis (1) Eclampsia (1) Esophagitis (1) Vaginal neoplasm (1) Cellulitis (1) Angioedema (1) Self-injurious behavior (1) Gastrointestinal stroma tumor (1) Bulimia (1) Neoplasm of the rectum (1) Chest pain (1) Atelectasis (1) Lymphocytosis (1) Polymenorrhea (1)

    HP:0002180: Neurodegeneration

    Developed by Shray Alag, The Harker School
    Sections: Correlations, Clinical Trials, and HPO

    Correlations computed by analyzing all clinical trials.

    Navigate: Clinical Trials and HPO


    Correlated Drug Terms (16)


    Name (Synonyms) Correlation
    drug2930 Placebo 0.20 mg + 2.00 mg/kg Wiki 0.71
    drug2992 Placebo- 2.00 mg/kg Wiki 0.71
    drug1270 Drug: GS-5734 - 2.00 mg/kg Wiki 0.71
    Name (Synonyms) Correlation
    drug2990 Placebo- 0.20 mg/kg Wiki 0.71
    drug2991 Placebo- 1.00 mg/kg Wiki 0.71
    drug1279 Drugs: NA-831 (0.10 mg/kg) plus GS-5734 (1.00 mg/kg) Wiki 0.71
    drug1275 Drug: NA-831 - 0.10 mg/kg Wiki 0.71
    drug1280 Drugs: NA-831 (0.20 mg/kg) plus GS-5734 (2.00 mg/kg) Wiki 0.71
    drug1269 Drug: GS-5734 - 1.00 mg/kg Wiki 0.71
    drug1276 Drug: NA-831 - 0.20 mg/kg Wiki 0.71
    drug2929 Placebo 0.10 mg + 1.00 mg/kg Wiki 0.71
    drug1747 Home exercise program Wiki 0.71
    drug2989 Placebo- 0.10 mg/kg Wiki 0.71
    drug4405 blood samples Wiki 0.50
    drug1511 Favipiravir Wiki 0.15
    drug2916 Placebo Wiki 0.03

    Correlated MeSH Terms (10)


    Name (Synonyms) Correlation
    D009410 Nerve Degeneration NIH 1.00
    D004660 Encephalitis NIH 0.71
    D012141 Respiratory Tract Infections NIH 0.11
    Name (Synonyms) Correlation
    D003141 Communicable Diseases NIH 0.10
    D014777 Virus Diseases NIH 0.07
    D007239 Infection NIH 0.07
    D013577 Syndrome NIH 0.06
    D011014 Pneumonia NIH 0.04
    D045169 Severe Acute Respiratory Syndrome NIH 0.03
    D018352 Coronavirus Infections NIH 0.03

    Correlated HPO Terms (3)


    Name (Synonyms) Correlation
    HP:0002383 Encephalitis HPO 0.71
    HP:0011947 Respiratory tract infection HPO 0.11
    HP:0002090 Pneumonia HPO 0.04

    Clinical Trials

    Navigate: Correlations   HPO

    There are 2 clinical trials


    1 Neurodegeneration Markers and Neurological Course in Severe Covid-19 Infection - MARNEVO-Covid

    Emergence of Covid-19 virus is associated with high frequency of extremely severe clinical pictures, with minor signs of CNS impairment (e.g. anosmia, headache). Since neurotropism is a common feature of coronavirus infection in animals, the investigators examine if indirect signs of CNS lesion are observed in association with severe Covid-19 infection.

    NCT04361344
    Conditions
    1. COVID-19 Infection
    2. Encephalitis
    Interventions
    1. Biological: blood samples
    MeSH:Infection Communicable Diseases Encephalitis Nerve Degeneration
    HPO:Encephalitis Neurodegeneration

    Primary Outcomes

    Description: Change of neurofilament light chain (NFL) (pg/ml) level between first day of hospitalisation and one week; and change of GFAP (pg/ml) level between first day of hospitalisation and one week.

    Measure: Change of neurodegeneration markers level

    Time: Level of neurofilament light chain (NFL) is dosed at inclusion (day 0) and week 1. Level of GFAP is dosed at inclusion (day 0) and week 1 (day 7).
    2 A Randomized, Placebo-controlled Study of the Safety, Tolerability and Pharmacokinetics of Inhaled Nanoparticle Formulation of Remdesivir (GS-5734) and in Combination With NA-831 in Healthy Volunteers

    The clinical study is designed to evaluate the safety, tolerability and pharmacokinetics of inhaled nanoparticle nanoparticle formulation of Remdesivir (GS-5734) alone and in combination with NA-831 in 48 healthy volunteers.

    NCT04480333
    Conditions
    1. Covid19
    2. Corona Virus Infection
    3. Severe Acute Respiratory Syndrome
    4. Severe Acute Respiratory Infection
    5. Severe Acute Respiratory Syndrome (SARS) Pneumonia
    6. Severe Acute Respiratory Syndrome of Upper Respiratory Tract
    7. Neurodegeneration
    8. Neuroinflammatory Response
    Interventions
    1. Drug: Drug: NA-831 - 0.10 mg/kg
    2. Drug: Placebo- 0.10 mg/kg
    3. Drug: Drug: NA-831 - 0.20 mg/kg
    4. Drug: Placebo- 0.20 mg/kg
    5. Drug: Drug: GS-5734 - 1.00 mg/kg
    6. Drug: Placebo- 1.00 mg/kg
    7. Drug: Drug: GS-5734 - 2.00 mg/kg
    8. Drug: Placebo- 2.00 mg/kg
    9. Combination Product: Drugs: NA-831 (0.10 mg/kg) plus GS-5734 (1.00 mg/kg)
    10. Combination Product: Placebo 0.10 mg + 1.00 mg/kg
    11. Combination Product: Drugs: NA-831 (0.20 mg/kg) plus GS-5734 (2.00 mg/kg)
    12. Combination Product: Placebo 0.20 mg + 2.00 mg/kg
    MeSH:Infection Communicable Diseases Respiratory Tract Infections Virus Diseases Severe Acute Respiratory Syndrome Coronavirus Infections Pneumonia Syndrome Nerve Degeneration
    HPO:Neurodegeneration Pneumonia Respiratory tract infection

    Primary Outcomes

    Description: AEs will be assessed using Common Terminology Criteria for Adverse Events (CTCAE) V5.0

    Measure: Proportion of Participants Experiencing any Treatment-Emergent Adverse Events

    Time: First dose date up to Day 30 Follow-up Assessment

    Description: This will be assessed at various time points by clinical laboratory tests and vital signs.

    Measure: Proportion of Participants Experiencing any Treatment-Emergent Graded Laboratory Abnormalities

    Time: First dose date up to Day 30 Follow-up Assessment

    Secondary Outcomes

    Description: Monitoring of the levels of drugs in subject sera at various time points to elucidate the maximum concentration (Cmax) of NA-831 and GS-5734 in human serum.

    Measure: Maximum Concentration (Cmax) - Pharmacokinetic Assessment

    Time: 7 days

    Description: Monitoring of the levels of drugs in subject sera at various time points to elucidate the time to maximum concentration (Tmax) of NA-831 and GS-5734 in human serum

    Measure: Time to Maximum Concentration (Tmax) - Pharmacokinetic Assessment

    Time: 7 days

    Description: Monitoring of the levels of drugs in subject sera at various time points to elucidate the area under the curve from time of administration to the last measurable of NA-831 and GS-5734

    Measure: AUC calculated from time of administration to the last measurable concentration (AUC0-last) - Pharmacokinetic Assessment

    Time: 7 days

    Description: Monitoring of the levels of drugs in subject sera at various time points to elucidate the area under the curve extrapolated to infinity (AUC0-∞) of NA-831 and GS-5734

    Measure: Area Under the Curve Extrapolated to Infinity (AUC0-∞)

    Time: 7 days

    Description: Monitoring of the levels of drugs in subject sera at various time points to elucidate the half-life (t1/2) of NA-831 and GS-5734 in human serum.

    Measure: Half-Life (t1/2) - Pharmacokinetic Assessment

    Time: 7 days

    Description: Monitoring of the levels of drugs in subject sera through various time points to elucidate the volume of distribution (Vd) of NA-831 and GS-5734 in human serum.

    Measure: Volume of Distribution (Vd) - Pharmacokinetic Assessment

    Time: 7 days

    Description: Monitoring of the levels of drugs in subject sera through at various time points to elucidate clearance [CL] of NA-831 and GS-5734 in human serum.

    Measure: Clearance [CL] - Pharmacokinetic Assessment

    Time: 7 days

    HPO Nodes


    Reports

    Data processed on September 26, 2020.

    An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.

    Drug Reports   MeSH Reports   HPO Reports  

    Interventions

    4,180 reports on interventions/drugs

    MeSH

    691 reports on MeSH terms

    HPO

    263 reports on HPO terms

    All Terms

    Alphabetical index of all Terms

    Google Colab

    Python example via Google Colab Notebook